Literature DB >> 33426060

EGFR-AS1 Promotes Bladder Cancer Progression by Upregulating EGFR.

Anbang Wang1, Aimin Jiang1, Xinxin Gan1, Zheng Wang1, Jinming Huang1, Kai Dong1, Bing Liu1, Linhui Wang1, Ming Chen1.   

Abstract

Long noncoding RNAs play an essential role in bladder cancer progression. The role of long noncoding RNA EGFR-AS1 in bladder cancer needs further study. We used clinical specimens to analyze the relationship between EGFR-AS1 and bladder cancer patients' characteristics. The functional experiments and mechanism studies were performed using qRT-PCR, transwell assay, survival analysis, and correlation analysis. We found that high expression of EGFR-AS1 was nearly related to aggressive bladder cancer and indicated poor prognosis for patients. The functional experiments in vivo and in vitro suggested that EGFR-AS1 promoted the proliferation and invasion of bladder cancer cells. Mechanically, EGFR-AS1 promoted the expression of EGFR by inhibiting the degradation of EGFR mRNA, thereby promoting the metastasis of bladder cancer. In addition, EGFR-AS1/EGFR may be involved in the immune-related pathways of bladder cancer. These studies indicate that the EGFR-AS1/EGFR pathway may be a potential diagnostic marker and therapeutic target for bladder cancer.
Copyright © 2020 Anbang Wang et al.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33426060      PMCID: PMC7781701          DOI: 10.1155/2020/6665974

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


  14 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

2.  S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy.

Authors:  W T Kim; J Kim; C Yan; P Jeong; S Y Choi; O J Lee; Y B Chae; S J Yun; S C Lee; W J Kim
Journal:  Ann Oncol       Date:  2014-03-14       Impact factor: 32.976

3.  Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.

Authors:  Padmanee Sharma; Arlene Siefker-Radtke; Filippo de Braud; Umberto Basso; Emiliano Calvo; Petri Bono; Michael A Morse; Paolo A Ascierto; Jose Lopez-Martin; Peter Brossart; Kristoffer Rohrberg; Begoña Mellado; Bruce S Fischer; Stephanie Meadows-Shropshire; Margaret K Callahan; Jonathan Rosenberg
Journal:  J Clin Oncol       Date:  2019-05-17       Impact factor: 44.544

4.  Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics.

Authors:  Tianyuan Zhou; Youngsoo Kim; A Robert MacLeod
Journal:  Methods Mol Biol       Date:  2016

5.  A DDX31/Mutant-p53/EGFR Axis Promotes Multistep Progression of Muscle-Invasive Bladder Cancer.

Authors:  Kei Daizumoto; Tetsuro Yoshimaru; Yosuke Matsushita; Tomoya Fukawa; Hisanori Uehara; Masaya Ono; Masato Komatsu; Hiro-Omi Kanayama; Toyomasa Katagiri
Journal:  Cancer Res       Date:  2018-02-13       Impact factor: 12.701

6.  Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

Authors:  Thomas Powles; Ignacio Durán; Michiel S van der Heijden; Yohann Loriot; Nicholas J Vogelzang; Ugo De Giorgi; Stéphane Oudard; Margitta M Retz; Daniel Castellano; Aristotelis Bamias; Aude Fléchon; Gwenaëlle Gravis; Syed Hussain; Toshimi Takano; Ning Leng; Edward E Kadel; Romain Banchereau; Priti S Hegde; Sanjeev Mariathasan; Na Cui; Xiaodong Shen; Christina L Derleth; Marjorie C Green; Alain Ravaud
Journal:  Lancet       Date:  2017-12-18       Impact factor: 79.321

7.  Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.

Authors:  Noura J Choudhury; Alexa Campanile; Tatjana Antic; Kai Lee Yap; Carrie A Fitzpatrick; James L Wade; Theodore Karrison; Walter M Stadler; Yusuke Nakamura; Peter H O'Donnell
Journal:  J Clin Oncol       Date:  2016-04-04       Impact factor: 44.544

Review 8.  Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery.

Authors:  Mohammad Abufaraj; Kilian Gust; Marco Moschini; Beat Foerster; Francesco Soria; Romain Mathieu; Shahrokh F Shariat
Journal:  Transl Androl Urol       Date:  2016-10

9.  Long noncoding RNA EGFR-AS1 promotes cell growth and metastasis via affecting HuR mediated mRNA stability of EGFR in renal cancer.

Authors:  Anbang Wang; Yi Bao; Zhenjie Wu; Tangliang Zhao; Dong Wang; Jiazi Shi; Bing Liu; Shuhan Sun; Fu Yang; Linhui Wang; Le Qu
Journal:  Cell Death Dis       Date:  2019-02-15       Impact factor: 8.469

10.  Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk.

Authors:  Mei Peng; Yanjun Huang; Ting Tao; Cai-Yun Peng; Qiongli Su; Wanjun Xu; Kwame Oteng Darko; Xiaojun Tao; Xiaoping Yang
Journal:  Sci Rep       Date:  2016-06-23       Impact factor: 4.379

View more
  4 in total

1.  Exploration of the Immune-Related Long Noncoding RNA Prognostic Signature and Inflammatory Microenvironment for Cervical Cancer.

Authors:  Hui Yao; Xiya Jiang; Hengtao Fu; Yinting Yang; Qinqin Jin; Weiyu Zhang; Wujun Cao; Wei Gao; Senlin Wang; Yuting Zhu; Jie Ying; Lu Tian; Guo Chen; Zhuting Tong; Jian Qi; Shuguang Zhou
Journal:  Front Pharmacol       Date:  2022-05-19       Impact factor: 5.988

2.  SBSN drives bladder cancer metastasis via EGFR/SRC/STAT3 signalling.

Authors:  Zhongqiu Zhou; Zhuojun Zhang; Han Chen; Wenhao Bao; Xiangqin Kuang; Ping Zhou; Zhiqing Gao; Difeng Li; Xiaoyi Xie; Chunxiao Yang; Xuhong Chen; Jinyuan Pan; Ruiming Tang; Zhengfu Feng; Lihuan Zhou; Lan Wang; Jianan Yang; Lili Jiang
Journal:  Br J Cancer       Date:  2022-04-28       Impact factor: 9.075

Review 3.  Progress in the Research and Targeted Therapy of ErbB/HER Receptors in Urothelial Bladder Cancer.

Authors:  Dong Chen; Yunlin Ye; Shengjie Guo; Kao Yao
Journal:  Front Mol Biosci       Date:  2021-12-23

4.  Hypoxia-induced long noncoding RNA NR2F1-AS1 maintains pancreatic cancer proliferation, migration, and invasion by activating the NR2F1/AKT/mTOR axis.

Authors:  Yanqing Liu; Shiyu Chen; Kun Cai; Dijie Zheng; Changhao Zhu; Lin Li; Feiqing Wang; Zhiwei He; Chao Yu; Chengyi Sun
Journal:  Cell Death Dis       Date:  2022-03-14       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.